Pacific Defense Selected for U.S. Army CMFF Program
27.3.2025 16:47:00 EET | Business Wire | Press release
Pacific Defense, the leader in C5ISR Modular Open Suite of Standards (CMOSS) products and integrated mission systems, has been selected for the contract definition phase of the United States Army’s CMOSS Mounted Form Factor (CMFF) Mounted Common Infrastructure (MCI), an Other Transaction Authority (OTA) contract evaluation. This phase aligns contract work scope and deliverables, fostering innovation and successful program execution post contract award. Leading a team of select industry partners that includes Thales Defense & Security Inc., BAE Systems, Palantir, MAXISIQ, Regal Technology Partners, and STC, an Arcfield company, Pacific Defense is ready to deploy a comprehensive capability set to accelerate the U.S. Army's vision for CMFF.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250327094467/en/
Pacific Defense CMOSS Mounted Form Factor (CMFF) revolutionizes communications, command, and control across U.S. Army ground and aviation platforms, enabling maneuver commanders to maintain a decisive advantage over peer and near-peer adversaries.
"The future of innovation for the warfighter and the defense industry is here today," said Travis Slocumb, CEO of Pacific Defense. "This milestone represents the culmination of years of hard work and collaboration with our Army and industry partners to deliver transformative solutions that are ready to meet the evolving needs of the modern battlefield. The foundational CMFF MCI investments across ground and aviation platforms unlocks an operating model that allows for rapid, iterative, and cost-effective insertion of hardware and software, significantly reducing the time to deploy and enhance systems.”
The CMFF program, led by PM Mission Command within Program Executive Office Command, Control, Communications, and Network (PEO C3N) at Aberdeen Proving Ground, is set to revolutionize communications, command, and control across U.S. Army ground and aviation platforms, enabling maneuver commanders to maintain a decisive advantage over peer and near-peer adversaries. Selected under an OTA, Mid-Tier Acquisition (MTA), this program accelerates the delivery of cutting-edge technology to the warfighter.
About Pacific Defense
Pacific Defense is purpose-built to drive the open systems transformation necessary to unlock rapid innovation and the power of commercial technology. Specializing in C5ISR and Electronic Warfare (EW) solutions for mission-critical environments, Pacific Defense leverages Modular Open Systems Architecture (MOSA) standards to deliver innovative, adaptable technology that enables faster response to emerging threats and evolving mission requirements. Learn more at www.pacific-defense.com and on LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250327094467/en/
Contacts
Pacific Defense Media Contact
Lea Ramthun - marketing@pacific-defense.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mosaic Therapeutics to Present Poster Highlighting Preclinical Data for Lead Program MOS101 at the American Association for Cancer Research (AACR) Annual Meeting 202624.3.2026 10:30:00 EET | Press release
Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) a clinical-stage oncology therapeutics company building the category leader in Synergistic Precision Oncology, today announced it will hold a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 17-22 in San Diego, CA. Poster Presentation Details: Title: "Combination of the MDM2 antagonist ASTX295 and olaparib as a novel treatment option for BRCA2 mutant, TP53 wild-type solid tumors” Abstract Number: 3053 Date and Time: Monday, April 20, 2026, 2:00PM – 5:00PM PST Session Category: Novel Targets and Pathways Session: PO.ET09.09 Location: Poster Section 15 For more information and to view the Company’s abstract, visit the AACR Annual Meeting website. About ASTX295 ASTX295 is a potent, highly selective, potentially best-in-class MDM2 antagonist that has completed a phase I study (NCT03975387) in over 100 patients with advanced solid tumors. Rationally designed to exhibit a
Vonage and ServiceNow Expand their Partnership24.3.2026 10:20:00 EET | Press release
Vonage, part of Ericsson (NASDAQ: ERIC), today announced the launch of its native integration with ServiceNow Voice, built on the ServiceNow AI Platform, embedding enterprise-grade voice and real-time AI capabilities directly into ServiceNow Customer Service Management (CSM) and IT Service Management (ITSM) workflows for Vonage Contact Center (VCC) customers. Vonage provides a unified service environment for enterprise customer service and IT support teams, enabling agents to deliver exceptional customer experiences while driving improvements to service performance. The integration of VCC with ServiceNow embeds real-time voice and AI capabilities into enterprise workflows, giving them the tools their agents need to streamline case progression, automate workflows, and reduce manual effort. Through the Vonage integration, calls can automatically trigger incident categorisation, initiate ServiceNow Flow Designer subflows, and update issue resolution data in real time, helping to reduce ma
Omnes Partners With Apex Group to Tokenise Institutional Bitcoin Mining Structured Note on Base24.3.2026 10:00:00 EET | Press release
Omnes today announced a strategic partnership with Apex Group, a leading global financial services provider with over $3.5 trillion in assets serviced, to tokenise its flagship Omnes Mining Note "OMN". The OMN is an institutional grade structured note backed by Bitcoin hashrate, to be issued and managed on the Base Chain, the Ethereum L2 incubating at Coinbase, leveraging Apex Digital 3.0 for comprehensive tokenisation, administration, and transfer agency services as a fully integrated end to end solution. The OMN provides professional non-US investors with direct economic exposure to new Bitcoin production measured in hashrate, which is the computational power used to validate transactions and produce Bitcoin, without the operational complexities of managing mining infrastructure, hardware, energy, or regulatory hurdles. Issued as a secured debt note in Luxembourg, the tokenised OMN combines traditional financial structuring with blockchain enabled features, including on chain transfe
Avanzanite Expands French Operations and Appoints Constance Sabbagh as General Manager24.3.2026 08:00:00 EET | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today announced its expansion into France, Europe’s second largest economy, and the appointment of Constance Sabbagh as General Manager, France. Following a €32 million Series A investment by MVM Partners announced in November 2025, Avanzanite is scaling its European infrastructure into a single, integrated platform across 32 countries – designed to bring rare disease medicines to patients in every European market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323639110/en/ Constance Sabbagh, General Manager, France “France is essential to Avanzanite’s European vision,” said Adam Plich, Co-founder and CEO of Avanzanite. “With its leadership in rare disease policy through its National Rare Disease Plans, care networks and scientific innovation, France is one of the most significant healthcare
AAD 2026: Galderma Showcases Latest Evidence Supporting Its Full-Spectrum, Science-Driven Solutions for Diverse Skin Needs24.3.2026 08:00:00 EET | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, will present the latest updates on its innovations across its broad portfolio at the 2026 American Academy of Dermatology (AAD) Annual Meeting, taking place from March 27-31 in Denver, Colorado. Twenty-two abstracts will be presented, including late-breaking data and three oral presentations spanning Therapeutic Dermatology, Injectable Aesthetics, and Dermatological Skincare. “Galderma is on a path towards becoming the undisputed dermatology powerhouse and, as such, aims to set the bar for scientific excellence in the field. The range of data we are presenting at AAD shows the strength of our commitment to this across every part of our portfolio. Patients deserve sophisticated, effective solutions that meet their diverse and evolving needs, and our science is built to deliver exactly that.” BALDO SCASSELLATI SFORZOLINI, M.D., PH.D. GLOBAL HEAD OF R&D AND CORPORATE DEVELOPMENT GALDERMA Therapeutic Dermatology: Latest updat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom